AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16709552
Drug: Olanzapine (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-15 mg/d)
Trial: 9407756
Drug: Naproxen granular
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen granular 500 mg
Trial: 8505452
Drug: Carbamide peroxide
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamide peroxide gel
Trial: 3429683
Drug: Prazosin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (twice daily for eight weeks)
Trial: 3429683
Drug: Prazosin (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (once daily for eight weeks)
Trial: 30839494
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon α2b 1 MU/mL
Trial: 23264335
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy (MM)
Trial: 16880100
Drug: PB127 (0.175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB127 (0.175 mg/kg diluted in 5% dextrose)
Trial: 16880100
Drug: Dipyridamole (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.56 mg/kg)
Trial: 10848655
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d., clarithromycin 250 mg b.d., tinidazole 500 mg b.d. for 7 days (OCT)
Trial: 23090499
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with all-trans retinoic acid and TAD (6-thioguanine, cytarabine, daunorubicin)
Trial: 23090499
Drug: TAD-HAM induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD-HAM induction (high dose cytarabine, mitoxantrone)
Trial: 17961576
Drug: Soy supplementation
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplementation (52 g of soy protein containing 112 mg of isoflavones) for 8 weeks
Trial: 17132972
Drug: Tramiprosate (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramiprosate (50, 100, or 150 mg twice daily for 12 weeks)
Trial: 14630680
Drug: Chemotherapy (more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (more intensive in GELA group)
Trial: 14630680
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection plus chemotherapy (GELD group)
Trial: 14630680
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (GELA group)
Trial: 12835883
Drug: Sucralfate 3
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate 3 g in 15 ml suspension enema
Trial: 12835883
Drug: Mesalazine 4
RxNorm normalized name: Mesalazine 400 mg gastro-resistant and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 4 g gel enema
Trial: 12835883
Drug: Hydrocortisone 100
RxNorm normalized name: hydrocortisone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 100 mg foam enema
Trial: 10389782
Drug: midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.5 mg/kg
Trial: 8540847
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at 120 mg/kg per day
Trial: 8540847
Drug: Ganciclovir sodium
RxNorm normalized name: Ganciclovir Sodium
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day
Trial: 8540847
Drug: Combination therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy: induction with the other drug for 2 weeks followed by maintenance therapy with both drugs (ganciclovir at 5 mg/kg per day and foscarnet at 90 mg/kg per day)
Trial: 1902405
Drug: Combination thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination thrombolytic therapy (both t-PA and urokinase)
Trial: 25444793
Drug: Intramuscular bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine (5 μg, 15 μg, 50 μg, and 150 μg doses)
Trial: 25444793
Drug: Intramuscular bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine
Trial: 21663486
Drug: Bifidobacterium lactis
RxNorm normalized name: bifidobacterium lactis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium lactis HN019 high dose (17.2 billion CFU)
Trial: 21663486
Drug: Bifidobacterium lactis
RxNorm normalized name: bifidobacterium lactis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium lactis HN019 low dose (1.8 billion CFU)
Trial: 17238412
Drug: Propbank-based Machine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propbank-based Machine Learning (ML) for annotating abstracts of Randomized Controlled Trials
Trial: 9024371
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (15 micrograms/kg)
Trial: 9024371
Drug: Control (nebulised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nebulised salbutamol at 2.5 mg or 5.0 mg, depending on age)
Trial: 8295467
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (1.2 J/point)
Trial: 8295467
Drug: Inactive laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive laser treatment (0 J/point)
Trial: 2950179
Drug: Sunscreen agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen agent
Trial: 2950179
Drug: Base used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base used in sunscreen preparation
Trial: 20674829
Drug: Combination azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination azelastine and fluticasone nasal spray
Trial: 14522298
Drug: Bupivacaine 0.75%
RxNorm normalized name: BUPivacaine 0.75% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.75% applied in 0.1 mL drops 3 times in the 30 minutes before surgery
Trial: 14522298
Drug: Bupivacaine 0.75%
RxNorm normalized name: BUPivacaine 0.75% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.75% applied in 0.1 mL drops 6 times in the 60 minutes before surgery
Trial: 9739895
Drug: Pristinamycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pristinamycin (1 g b.i.d. for 10 days)
Trial: 9739895
Drug: Oxacillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxacillin (1 g b.i.d. for 10 days)
Trial: 3516619
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with azathioprin and steroids (Group A)
Trial: 3516619
Drug: Antilymphocyte globulin
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphocyte globulin (ALG) for three weeks plus azathioprin and steroids (Group B)
Trial: 3516619
Drug: ALG-azathioprin-steroid administration
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ALG-azathioprin-steroid administration for a mean of nine days followed by ciclosporin (Group C)
Trial: 29165732
Drug: Melatonin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (20 mg/d)
Trial: 16510862
Drug: Intensified, multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified, multicomponent geriatric treatment
Trial: 11529973
Drug: sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sequential methotrexate and 5-fluorouracil (MF)
Trial: 9088820
Drug: Post-operative oral
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative oral diazepam
Trial: 8225043
Drug: Tocolytic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolytic and antibiotic therapy
Trial: 31447072
Drug: AVF surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVF surgical creation with placement of the VasQ implant
Trial: 31447072
Drug: AVF surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVF surgical creation without the implant (control)
Trial: 25225151
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Boswellia serrata L. and Cyperus scariosus L. (2g) plus pelvic floor muscle training
Trial: 21887727
Drug: Adalimumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (both dosing regimens)
Trial: 20134178
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg ropivacaine with 20 microg fentanyl
Trial: 20134178
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg hyperbaric bupivacaine with 20 microg fentanyl
Trial: 16973987
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of montelukast and salmeterol
Trial: 12225329
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride (HDC) in combination with IFN-alpha-2b, 3 MIU, three times weekly via subcutaneous injection, with HDC doses of 1 mg either once a day, three times a week; once a day, five times a week; twice a day, three times a week; or twice a day, five times a week.
Trial: 9799034
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg daily for 6 months)
Trial: 9799034
Drug: Doxazosin (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (9 mg daily for 6 months)
Trial: 1989962
Drug: Monthly written
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly written reports
Trial: 21544071
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg for 7 days)
Trial: 21544071
Drug: Bupropion (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (150 mg for 7 days)
Trial: 17702699
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba treatment (240 mg daily) during the first 12 weeks and supervised exercise training during the second 12 weeks
Trial: 17702699
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment during the first 12 weeks and supervised exercise training during the second 12 weeks
Trial: 11723262
Drug: Zonisamide 400
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 400 mg/d
Trial: 11723262
Drug: Zonisamide 100
RxNorm normalized name: zonisamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 100 mg/d
Trial: 11723262
Drug: Zonisamide 200
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 200 mg/d
Trial: 9160129
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg IM every 8 hours
Trial: 9160129
Drug: Metamizol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol 2 g IM every 8 hours
Trial: 19819436
Drug: High-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.35 mg isoflavones/day)
Trial: 19819436
Drug: Low-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg isoflavones/day)
Trial: 15644045
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 9 MU interferon-alpha2a followed by weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Trial: 15644045
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Trial: 12574761
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation home program (specific details on dosage and duration not provided)
Trial: 8762852
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of anti-mycobacterial antibodies
Trial: 8762852
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of IgG or anti-mycobacterial antibodies or both
Trial: 8762852
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of IgG or anti-mycobacterial antibodies in other cases
Trial: 22250993
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC), 3000 mg/day of elemental lanthanum
Trial: 16222899
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg force-titrated to 80 mg after 1 month (n = 25)
Trial: 16222899
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg force-titrated to 5 mg after 1 month (n = 25)
Trial: 16222899
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg plus Ramipril 2.5 mg (n = 25)
Trial: 2676910
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg per day cyclosporin A (CsA)
Trial: 799997
Drug: Cephradine (25-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine (25-110 mg/kg per day) for 5-15 days
Trial: 799997
Drug: Cephalexin (25-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (25-150 mg/kg per day) for 5-15 days
Trial: 29880175
Drug: 1700 mg
RxNorm normalized name: inulin 1700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1700 mg metformin
Trial: 19794198
Drug: Optimised care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised care model with training on diagnosis and treatment of anxiety disorders and psychiatric consultation-liaison service for 6 months
Trial: 12544454
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg indapamide SR
Trial: 10839487
Drug: Cefdinir 600
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 600 mg once daily (OD)
Trial: 10839487
Drug: Cefdinir 300
RxNorm normalized name: cefdinir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir 300 mg every 12 hours (BD)
Trial: 10839487
Drug: Amoxicillin/clavulanate 500/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 500/125 mg every 8 hours
Trial: 8939177
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 4 mg, given four times daily for 16 weeks
Trial: 8939177
Drug: Albuterol 200
RxNorm normalized name: ALBUTEROL 200MCG CAP,INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 200 micrograms, given four times daily for 16 weeks
Trial: 17021584
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BT‐A) injection at gastrocnemius
Trial: 17021584
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BT‐A) injection at adductors
Trial: 17021584
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BT‐A) injection at gastrocnemius and adductors
Trial: 16164922
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (AI) formestane
Trial: 16164922
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aromatase inhibitor)
Trial: 16164922
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antibodies)
Trial: 12450691
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections of BCG
Trial: 10225312
Drug: Intra-oesophageal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-oesophageal lidocaine 20 mg/ml
Trial: 25937443
Drug: Desmoteplase (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmoteplase (90 μg/kg) given 3-9 h after symptom onset
Trial: 21056069
Drug: Soluble fiber
RxNorm normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble fiber dextrin (12 g)
Trial: 21056069
Drug: Soluble corn
RxNorm normalized name: soluble corn fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble corn fiber (11.8 g)
Trial: 21056069
Drug: Polydextrose (11.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (11.8 g)
Trial: 21056069
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (11.2 g)
Trial: 19277873
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management therapy (20 sessions of 2 hours each) and usual health care by a cardiologist
Trial: 15327428
Drug: r‐halphaGalA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐halphaGalA (1 mg/kg body weight continuously infused over 4 hours) during dialysis
Trial: 15327428
Drug: r‐halphaGalA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐halphaGalA (1 mg/kg body weight) administered separately in the interval between dialysis treatments
Trial: 9158882
Drug: Ormaplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ormaplatin (30 min intravenous infusion)
Trial: 3669756
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with recombinant alpha 2b-interferon for 6 months after initial 12 months.
Trial: 3669756
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after initial 12 months of interferon therapy.
Trial: 28681267
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen (800 mg in 100 ml normal saline)
Trial: 28681267
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (1 g in 100 ml normal saline)
Trial: 16081469
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation (high-dose combination of calcium, magnesium, zinc, copper, selenium, vitamin A, thiamine, riboflavin, vitamin B6, folate, vitamin B12, vitamin C, vitamin E, vitamin D, Coenzyme Q10) for 9 months
Trial: 10400846
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of fexofenadine HCl twice daily
Trial: 10400846
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of sustained‐release pseudoephedrine HCl twice daily
Trial: 10400846
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of fexofenadine HCl/120 mg of sustained‐release pseudoephedrine HCl twice daily
Trial: 7477169
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus intensive chemotherapy and autologous bone marrow transplantation
Trial: 7477169
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without transplantation
Trial: 219470
Drug: procetofen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: procetofen (3 x 100 mg/day for 4-6 weeks)
Trial: 27406859
Drug: Tomato products
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato products containing 30 mg lycopene per day